The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
The drug company has set prices for Ozempic and Wegovy much higher than in other countries. The committee found earlier this year that NovoNordisk charges Americans with diabetes $969 a month ...
Senators grilled the top executive of NovoNordisk over why the Danish company charges Americans far more for the blockbuster weight-loss drug Wegovy and diabetes drug Ozempic than it does ...